GlassScriptPhysician profile
Donald J Benz
NPI 1689669475
$14,283.31
in general payments reported to CMS, 2019-2025
33 companies · $49.80 in 2025
The $49.80 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,392 · 2020: $3,497 · 2021: $5,443 · 2022: $1,559 · 2023: $95.77 · 2024: $247 · 2025: $49.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $2,529.17 | 2019-2022 | |
| Amgen INC. | $1,654.59 | 2019-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,380.66 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,034.12 | 2019-2021 | |
| Pfizer INC. | $936.79 | 2019-2021 | |
| Lilly USA, LLC | $833.23 | 2019-2022 | |
| Abbvie INC. | $785.82 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $682.54 | 2019-2022 | |
| Amarin Pharma, INC. | $577.33 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $453.96 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $410.11 | 2019-2022 | |
| Daiichi Sankyo INC. | $388.94 | 2019-2021 | |
| Novo Nordisk INC | $388.57 | 2019-2022 | |
| Glaxosmithkline, LLC. | $348.03 | 2019-2021 | |
| Allergan, INC. | $236.20 | 2019-2020 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $204.59 | 2019 | |
| Medicure Pharma INC. | $197.31 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.82 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.06 | 2022 | |
| Intercept Pharmaceuticals, INC. | $122.76 | 2021 | |
| Sunovion Pharmaceuticals INC. | $122.50 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $109.52 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $106.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $97.91 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $85.59 | 2021 | |
| Grifols USA, LLC | $70.63 | 2019 | |
| Astellas Pharma US INC | $67.75 | 2019-2020 | |
| Madrigal Pharmaceuticals | $49.80 | 2025 | Rezdiffra |
| Teva Pharmaceuticals USA, INC. | $34.13 | 2019 | |
| Merck Sharp & Dohme LLC | $26.62 | 2019 | |
| Genentech USA, INC. | $21.59 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.08 | 2019 | |
| Gilead Sciences, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Benz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.